Mydecine Innovations Group Inc. (MYCO.NE)
| Previous Close | 0.8900 |
| Open | 0.8900 |
| Bid | 0.7500 x N/A |
| Ask | 0.8500 x N/A |
| Day's Range | 0.7600 - 0.9000 |
| 52 Week Range | 0.6600 - 30.0000 |
| Volume | |
| Avg. Volume | 51,488 |
| Market Cap | 181.401M |
| Beta (5Y Monthly) | 4.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1150 |
| Earnings Date | Nov 16, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation
DENVER, June 17, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (FDA) has cleared MYCO-001 in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product. The Investigator Initiated trial is funded by a near $4 million grant
- GlobeNewswire
Mydecine Provides Company Update; Welcomes New Board Member
DENVER, June 09, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today provided an update on clinical trial and drug development initiatives, and appointed a new member to its Board of Directors. Corporate Update "As we near the end of the second quarter, I’m proud of the progress our team has made despite the volatile an
- CNW Group
Mydecine Announces Closing of Overnight Marketed Public Offering of Units
Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is pleased to announce that it has closed its previously announced best efforts overnight marketed offering (the "Offering") of units (the "Units") through a syndicate of agents led by Stifel Nicolaus Canada Inc. ("Stifel GMP") and Roth Canada, Inc. (together with Stifel GMP, the "Agents"). Under the Offering, the Company issued 2,447,130 Units at a price per Unit of $1.15 for aggregate gross proce
